Loading...
OTCM
ATHXQ
Market cap6kUSD
Jul 08, Last price  
0.00USD
Name

Athersys Inc

Chart & Performance

D1W1MN
OTCM:ATHXQ chart
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-36.09%
Rev. gr., 5y
13.37%
Revenues
5m
-3.43%
2,152,00003,596,00003,260,0003,105,0002,159,0008,939,00010,344,0007,380,000755,000286,00010,298,00016,238,0002,843,00023,737,0005,517,0001,432,0005,514,0005,325,000
Net income
-68m
L-21.73%
-33,161,0000-14,599,000-1,511-18,926,000-17,992,000-15,366,000-11,377,000-13,746,000-14,735,000-30,743,000-22,082,000-16,422,000-15,337,000-32,241,000-24,283,000-44,582,000-78,765,000-86,955,000-68,061,000
CFO
-59m
L-22.62%
1,000-12,118,000-1,511-12,066,000-15,711,000-4,619,000-10,591,000-14,489,000-17,665,000-22,784,000-25,791,000-13,764,000-10,931,000-24,018,000-13,350,000-35,326,000-61,810,000-76,185,000-58,950,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
URL
https://www.athersys.com/home/default.aspx
IPO date
Apr 23, 2007
Employees
24
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT